Industry
Drug Manufacturers - Specialty & Generic
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Loading...
Open
0.76
Mkt cap
21M
Volume
16K
High
0.76
P/E Ratio
-0.91
52-wk high
2.12
Low
0.71
Div yield
N/A
52-wk low
0.59
Portfolio Pulse from Benzinga Newsdesk
August 22, 2024 | 10:52 am
Portfolio Pulse from Benzinga Newsdesk
August 16, 2024 | 4:12 pm
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 1:03 pm
Portfolio Pulse from Benzinga Newsdesk
July 29, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
July 22, 2024 | 5:02 pm
Portfolio Pulse from Benzinga Newsdesk
May 31, 2024 | 10:17 am
Portfolio Pulse from Benzinga Newsdesk
May 30, 2024 | 1:04 pm
Portfolio Pulse from Benzinga Newsdesk
May 16, 2024 | 12:29 pm
Portfolio Pulse from Benzinga Newsdesk
May 01, 2024 | 10:13 am
Portfolio Pulse from Benzinga Newsdesk
April 22, 2024 | 9:40 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.